An educational program for women with breast, ovarian & gynecological cancers. Learn about clinical trials for cancer treatment from the Medical Director for Clinical Trials at NYU Langone Medical Center, and from an experienced patient advocate.
Support Connection, Inc. announces an educational toll-free teleconference: "Understanding Clinical Trials for Breast and Gynecological Cancers." The program is open to women living with breast, ovarian and gynecological cancers. To learn more or to pre-register (PRE-REGISTRATION IS REQUIRED) call Support Connection at 914-962-6402 or 800-532-4290.
The teleconference will take place on Feb. 7, from 8-9:30 pm (NY Time) and topics will include:
• What are clinical trials and what are the different phases?
• Why are clinical trials important?
• How is patient participation important to clinical trials?
• How does one weigh the benefits and risks of participating, and what are the safeguards for patients?
• What are some barriers to participation?
• As a patient, what is it like to participate in a clinical trial and how does one find them?
A question and answer period will follow the presentation.
There will be two speakers:
• Yelena Novik, M.D. is an Assistant Professor and the Medical Director for Clinical Trials at NYU Langone Medical Center. Dr. Novik's medical specialties and expertise include cancer, medical oncology, breast cancer and melanoma.
• Gwen Harding-Peets, PhD, is an ovarian cancer survivor and a patient advocate. She has volunteered with Support Connection, SHARE, Survivors Teaching Students, and as a Peer Reviewer for the Dept. of Defense's Congressionally Directed Medical Research Program for Ovarian Cancer.
The teleconference is free. Women interested in participating should call Support Connection in advance to register and receive instructions. On the night of the teleconference, participants will call a special toll-free number and be connected with the group. To learn more or to register, call Support Connection at 914-962-6402 or 1-800-532-4290.
Funding for this program has been provided by a contribution from Genomic Health Inc.